SLC5A2 and type 2 diabetes mellitus: Recently, a retrospective study on Korean patients reported that higher baseline HbA1c level and preserved eGFR were predictive markers of better glycemic responses to an another class of SGLT2 inhibitor (dapagliflozin) [15]; specifically, female and obese T2DM patients tended to lose more weight during dapagliflozin treatment.